adjust
age
sex
bodi
mass
index
current
smoke
statu
forc
expiratori
volum
second
coronari
heart
diseas
hypertens
diabet
mellitu
chronic
obstruct
pulmonari
diseas
tumour
clinic
stage
risk
develop
postop
morbid
significantli
higher
lowest
serum
level
quartil
highest
quartil
hazard
ratio
ci
nsclc
patient
serum
level
ngml
significantli
higher
rate
pneumonia
pleural
effus
atrial
fibril
well
higher
inhospit
mortal
major
pulmonari
resect
compar
serum
level
serum
level
one
day
post
surgeri
independ
risk
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
thu
could
use
prognost
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
major
comorbid
patient
nonsmal
cell
lung
cancer
nsclc
cardiovascular
natur
report
incid
cardiovascular
diseas
describ
major
risk
factor
morbid
mortal
follow
surgeri
nsclc
reninangiotensin
system
ra
play
crucial
role
cardiovascular
regul
ra
angiotensinconvert
enzym
ace
metabolis
angiotensin
explor
associ
serum
angiotensinconvert
enzym
level
postop
morbid
mortal
major
pulmonari
resect
nonsmal
cell
lung
cancer
nsclc
patient
preoper
postop
serum
level
nsclc
patient
underw
major
pulmonari
resect
measur
serum
level
postop
day
divid
quartil
categori
ang
form
angiotensin
ii
ang
ii
exert
direct
trophic
action
cardiovascular
cell
local
ang
ii
product
key
import
pathophysiolog
ra
cardiovascular
system
recent
new
member
ra
found
function
neg
regul
ang
system
metabolis
ang
ii
put
protect
peptid
ang
high
effici
express
activ
tissu
highest
express
observ
endothelium
lung
heart
wide
accept
critic
balanc
activ
aceang
ii
axi
thu
play
pivot
role
bodi
endogen
regul
ra
present
studi
first
time
explor
associ
serum
level
postop
morbid
mortal
major
pulmonari
resect
nsclc
patient
januari
march
han
chines
nsclc
patient
underw
major
pulmonari
resect
enrol
studi
inclus
criteria
includ
definit
diagnos
nsclc
underw
major
pulmonari
resect
includ
lobectomi
bilobectomi
pneumonectomi
segmentectomi
wedg
resect
receiv
treatment
nsclc
pulmonari
resect
patient
concurr
malign
congenit
heart
diseas
previou
cardiovascular
surgic
histori
exclud
studi
approv
ethic
committe
second
xiangya
hospit
central
south
univers
start
studi
particip
provid
written
inform
consent
oper
perform
gener
anaesthesia
later
thoracotomi
complet
radic
systemat
lymphadenectomi
stage
reevalu
accord
seventh
edit
tnm
classif
histolog
type
carri
accord
world
health
organ
histolog
classif
morbid
defin
postop
event
pneumonia
prolong
air
leak
postop
chest
tube
drainag
day
atrial
fibril
pleural
effus
requir
renew
drainag
oper
mortal
defin
inhospit
mortal
blood
sampl
drawn
preoper
day
preoper
day
postop
day
postop
respect
blood
sampl
subject
elisa
assay
serum
level
use
human
elisa
kit
purchas
biovis
milpita
ca
usa
serum
level
divid
quartil
categori
ngml
adjust
hazard
ratio
hr
confid
interv
ci
calcul
use
cox
proport
hazard
model
continu
variabl
valu
express
mean
ae
sd
comparison
mean
two
group
perform
student
test
categor
variabl
express
n
analys
chisquar
test
fisher
exact
test
appropri
statist
analys
perform
sa
statist
signific
level
studi
set
twotail
serum
level
measur
blood
sampl
collect
preoper
day
preoper
day
postop
day
postop
day
shown
fig
serum
level
nsclc
patient
baselin
level
preoper
peak
hour
major
pulmonari
resect
return
baselin
level
three
day
surgeri
divid
serum
level
postop
day
quartil
categori
ng
ml
shown
tabl
signific
differ
among
quartil
categori
age
sex
bodi
mass
index
bmi
current
smoke
statu
forc
expiratori
volum
second
preval
coronari
heart
diseas
hypertens
diabet
mellitu
chronic
obstruct
pulmonari
diseas
copd
also
signific
differ
among
quartil
categori
distribut
nsclc
histolog
clinic
stage
tabl
shown
tabl
postop
morbid
increas
descend
quartil
serum
level
risk
significantli
higher
first
quartil
second
third
fourth
quartil
model
adjust
age
sex
bmi
current
smoke
statu
coronari
heart
diseas
hypertens
diabet
mellitu
copd
tumour
clinic
stage
model
risk
develop
postop
morbid
significantli
higher
lowest
serum
level
quartil
highest
quartil
hazard
ration
ci
p
examin
associ
lowest
serum
level
quartil
ngml
incid
figur
preoper
postop
serum
angiotensinconvert
enzym
level
nonsmal
cell
lung
cancer
patient
undergo
major
pulmonari
resect
typic
morbid
major
pulmonari
resect
includ
pneumonia
prolong
air
leak
pleural
effus
atrial
fibril
analys
combin
second
third
fourth
quartil
serum
level
one
categori
ngml
n
compar
first
serum
level
quartil
ngml
n
shown
tabl
nsclc
patient
serum
level
significantli
higher
rate
pneumonia
pleural
effus
atrial
postop
morbid
fibril
well
higher
inhospit
mortal
major
pulmonari
resect
compar
serum
level
analys
method
pulmonari
resect
reveal
serum
level
signific
effect
rate
postop
morbid
inhospit
mortal
patient
undergo
pneumonectomi
n
tabl
howev
patient
undergo
lobectomybilobectomi
n
serum
level
significantli
higher
rate
pleural
effus
atrial
fibril
serum
level
tabl
accord
data
tabl
patient
undergo
pneumonectomi
higher
rate
postop
morbid
inhospit
mortal
undergo
lobectomybilobectomi
preval
cardiovascular
diseas
lung
cancer
patient
known
twice
high
gener
popul
numer
report
neg
impact
cardiovascular
comorbid
postop
outcom
pulmonari
resect
patient
nsclc
endogen
regul
ra
play
crucial
role
cardiovascular
regul
present
studi
provid
first
evid
serum
level
associ
postop
morbid
mortal
major
pulmonari
resect
nsclc
patient
highli
express
lung
membranebound
protein
vascular
endothelium
alveolar
epitheli
cell
smooth
muscl
cell
pulmonari
vasculatur
bronchial
epithelia
pulmonari
appear
role
regul
balanc
circul
ang
ii
ang
level
ang
ii
induc
pulmonari
vasoconstrict
respons
hypoxia
import
prevent
shunt
patient
lung
injuri
local
increas
ang
ii
product
also
trigger
increas
vascular
permeabl
facilit
pulmonari
oedema
recent
studi
suggest
protect
sever
acut
lung
failur
copd
possibl
pulmonari
arteri
hypertens
protein
also
appear
entrypoint
receptor
sever
acut
respiratori
syndrom
sar
coronaviru
addit
interplay
ace
reportedli
play
pivot
role
develop
tubercul
pleural
effus
thu
appear
directli
involv
pulmonari
vascular
regul
well
pulmonari
infect
pleural
effus
agreement
previou
studi
found
present
studi
serum
level
lowest
quartil
associ
significantli
higher
rate
pneumonia
pleural
effus
major
pulmonari
resect
nsclc
patient
pan
et
al
examin
express
fibril
atria
pig
involv
fibrot
pathogenesi
atrial
fibril
studi
result
suggest
downregul
may
associ
pacinginduc
sustain
atrial
fibril
line
report
found
present
studi
serum
level
lowest
quartil
associ
significantli
higher
rate
atrial
fibril
major
pulmonari
resect
nsclc
patient
high
rate
postop
morbid
patient
serum
level
lowest
quartil
suffici
explain
increas
inhospit
mortal
rate
patient
pneumonectomi
common
type
pulmonari
resect
perform
patient
offer
cur
resect
primari
lung
cancer
howev
despit
improv
oper
techniqu
postop
care
pneumonectomi
remain
highrisk
procedur
agreement
patient
undergo
pneumonectomi
higher
rate
postop
morbid
inhospit
mortal
undergo
lobectomybilobectomi
studi
found
serum
level
nsclc
patient
significantli
elev
hour
major
pulmonari
resect
return
baselin
level
day
postop
therefor
serum
level
postop
day
use
subsequ
hazard
ratio
associ
analys
high
preval
cardiovascular
diseas
lung
cancer
patient
explain
common
risk
factor
older
age
tobacco
consumpt
thu
hazard
ratio
analysi
adjust
age
current
smoke
statu
varieti
confound
factor
may
affect
incid
postop
morbid
andor
serum
level
includ
sex
bmi
coronari
heart
diseas
hypertens
diabet
mellitu
copd
tumour
clinic
stage
adjust
confound
factor
risk
develop
postop
morbid
remain
significantli
higher
lowest
serum
level
quartil
highest
quartil
postop
day
indic
serum
level
one
day
post
surgeri
independ
risk
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
thu
serum
level
one
day
post
surgeri
could
use
biomark
prognost
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
addit
find
also
suggest
supplement
could
potenti
therapi
prevent
improv
postop
morbid
major
pulmonari
resect
given
import
role
ang
signal
pulmonari
vascular
regul
pulmonari
infect
pleural
effus
possibl
atrial
fibril
increas
major
pulmonari
tabl
associ
serum
angiotensinconvert
enzym
level
postop
morbid
inhospit
mortal
patient
undergo
lobectomybilobectomi
postop
morbid
resect
albeit
shortliv
may
critic
compensatori
mechan
initi
earli
postop
morbid
lead
reduc
manifest
postop
morbid
mortal
studi
need
uncov
underli
mechan
studi
prospect
studi
multipl
measur
serum
level
enabl
us
conduct
studi
control
manner
thu
gener
reliabl
data
sever
limit
studi
assess
shortterm
outcom
studi
nevertheless
evalu
longterm
surviv
outcom
underway
patient
cohort
studi
suggest
serum
level
one
day
post
surgeri
could
use
prognost
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
clinic
applic
valu
still
need
valid
futur
studi
larger
patient
popul
although
total
number
patient
undergo
major
pulmonari
resect
well
enough
achiev
studi
object
small
number
patient
underw
pneumonectomi
thu
stratifi
analys
pneumonectomi
lobectomi
rel
small
sampl
size
patient
undergo
pneumonectomi
n
may
adequ
achiev
result
adequ
statist
power
find
signific
effect
serum
level
postop
morbid
inhospit
mortal
patient
undergo
pneumonectomi
n
like
due
inadequ
sampl
size
serum
level
one
day
post
surgeri
independ
risk
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
low
serum
level
associ
increas
rate
postop
morbid
well
higher
inhospit
mortal
major
pulmonari
resect
nsclc
patient
thu
serum
level
one
day
post
surgeri
resect
could
use
prognost
factor
postop
morbid
major
pulmonari
resect
nsclc
patient
